Allied Investment Advisors LLC Grows Stake in Pfizer Inc. (NYSE:PFE)

Allied Investment Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 262,737 shares of the biopharmaceutical company’s stock after purchasing an additional 3,534 shares during the period. Allied Investment Advisors LLC’s holdings in Pfizer were worth $6,970,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Bank of Jackson Hole Trust purchased a new position in shares of Pfizer in the fourth quarter worth $264,000. Callahan Advisors LLC grew its stake in Pfizer by 16.5% during the fourth quarter. Callahan Advisors LLC now owns 488,294 shares of the biopharmaceutical company’s stock valued at $12,954,000 after acquiring an additional 69,155 shares in the last quarter. Mcdonald Partners LLC increased its holdings in Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Pfizer by 36.8% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 229,513 shares of the biopharmaceutical company’s stock worth $6,089,000 after purchasing an additional 61,737 shares in the last quarter. Finally, Davidson Trust Co. boosted its holdings in shares of Pfizer by 14.6% during the 4th quarter. Davidson Trust Co. now owns 39,656 shares of the biopharmaceutical company’s stock valued at $1,052,000 after purchasing an additional 5,062 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $25.56 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market cap of $144.82 billion, a PE ratio of 18.12, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a 50-day moving average price of $26.26 and a 200 day moving average price of $27.46.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The company’s quarterly revenue was up 24.7% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.73%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PFE shares. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.